<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01090752</url>
  </required_header>
  <id_info>
    <org_study_id>FDAAA</org_study_id>
    <nct_id>NCT01090752</nct_id>
  </id_info>
  <brief_title>Renal and Hormonal Effects of Pioglitazone</brief_title>
  <official_title>Effects of the PPAR-gamma Agonist Pioglitazone on Renal and Hormonal Responses to Salt in Diabetic and Hypertensive Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Geneva</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Lausanne Hospitals</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Geneva</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study examines the effects of pioglitazone on renal sodium handling in subjects prone to
      insulin resistance, i.e. diabetic and/or hypertensive subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim: Glitazones are powerful insulin sensitizers prescribed for the treatment of type 2
      diabetes. Their use is however associated with fluid retention and an increased risk of
      congestive heart failure. We previously demonstrated that pioglitazone increases proximal
      sodium reabsorption in healthy volunteers. This study examines the effects of pioglitazone on
      renal sodium handling in subjects prone to insulin resistance, i.e. diabetic and/or
      hypertensive subjects.

      Methods: In this double-blind, randomized, placebo-controlled, four-way, cross-over study, we
      examined the effects of pioglitazone (45mg daily during 6 weeks) or placebo on renal,
      systemic and hormonal responses to changes in sodium intake in 16 individuals, 8 with type 2
      diabetic and 8 with hypertension.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effects of Pioglitazone on Renal Hemodynamics</measure>
    <time_frame>2008</time_frame>
    <description>At the end of each treatment diet phase, renal clearances were performed for the determination of GFR and RBF</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effects of Pioglitazone on Sodium and Lithium Clearances</measure>
    <time_frame>2007</time_frame>
    <description>At the end of each treatment and diet phase, 24 urine collections were collected for the determination of sodium and lithium clearances</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effects of Pioglitazone on 24h Blood Pressure Control</measure>
    <time_frame>march 2009</time_frame>
    <description>24 hour blood pressure measurements were performed after each treatment/diet phase</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effects of Pioglitazone on Salt Sensitivity</measure>
    <time_frame>2009</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Diabetes</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Pioglitazone</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo-controlled, randomized, cross-over study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo-controlled, randomized, cross-over study was to explore the effects of pioglitazone (45 mg q.d. for 6 weeks) on the renal, hormonal and blood pressure responses to changes in sodium intake in a population prone to insulin resistance</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone</intervention_name>
    <description>placebo-controlled, randomized, cross-over study was to explore the effects of pioglitazone (45 mg q.d. for 6 weeks) on the renal, hormonal and blood pressure responses to changes in sodium intake in a population prone to insulin resistance</description>
    <arm_group_label>Pioglitazone</arm_group_label>
    <other_name>Actos</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>placebo-controlled, randomized, cross-over study was to explore the effects of pioglitazone (45 mg q.d. for 6 weeks) on the renal, hormonal and blood pressure responses to changes in sodium intake in a population prone to insulin resistance</description>
    <arm_group_label>Pioglitazone</arm_group_label>
    <arm_group_label>Metformine</arm_group_label>
    <other_name>Glucophage</other_name>
    <other_name>Glumetza</other_name>
    <other_name>Fortamet</other_name>
    <other_name>Riomet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type II Diabetes

          -  Hypertension

        Exclusion Criteria:

          -  Cardiac or renal diseases

          -  Anaemia

          -  Drugs like aspirin, non steroidal anti-inflammatory drugs and hormonal replacement
             therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antoinette Pechere-Bertschi, MD</last_name>
    <role>Study Director</role>
    <affiliation>Geneva University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pech√®re-Bertschi Antoinette</name>
      <address>
        <city>Geneva</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2010</study_first_submitted>
  <study_first_submitted_qc>March 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2010</study_first_posted>
  <results_first_submitted>March 24, 2010</results_first_submitted>
  <results_first_submitted_qc>March 24, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 8, 2010</results_first_posted>
  <last_update_submitted>March 24, 2010</last_update_submitted>
  <last_update_submitted_qc>March 24, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2010</last_update_posted>
  <responsible_party>
    <name_title>University Hospital Geneva</name_title>
    <organization>University Hospital Geneva</organization>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>blood pressure</keyword>
  <keyword>pioglitazone</keyword>
  <keyword>sodium</keyword>
  <keyword>insulin resistance, renal function, sodium, pioglitazone</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Sixteen subjects were examined, 8 with a diagnosis of type 2 diabetes (DM2) and 8 with a diagnosis of systemic hypertension (HTN). The participants were recruited by hospital placards detailing the study, and through ambulatory care centers in Lausanne and Geneva.</recruitment_details>
      <pre_assignment_details>Each subject was randomised to receive either pioglitazone or placebo for 6 weeks, with a 2 week wash-out period between the two treatment phases. Randomisation of the sequences of placebo and active treatment periods were performed by a doctor having no contact with participants and clinicians.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Pioglitazone Low Salt/High Salt</title>
          <description>a low salt and a high salt diet were given consequently and randomly during a week at the end of the pioglitazone phase</description>
        </group>
        <group group_id="P2">
          <title>Placebo Low Salt/High Salt</title>
          <description>a low salt and a high salt diet were given consequently and randomly during a week at the end of the placebo phase</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pioglitazone Low Salt/High Salt</title>
          <description>a low salt and a high salt diet were given consequently and randomly during a week at the end of the pioglitazone phase</description>
        </group>
        <group group_id="B2">
          <title>Placebo Low Salt/High Salt</title>
          <description>a low salt and a high salt diet were given consequently and randomly during a week at the end of the placebo phase</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.5" spread="2.8"/>
                    <measurement group_id="B2" value="52.5" spread="2.8"/>
                    <measurement group_id="B3" value="52.5" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Effects of Pioglitazone on Renal Hemodynamics</title>
        <description>At the end of each treatment diet phase, renal clearances were performed for the determination of GFR and RBF</description>
        <time_frame>2008</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pioglitazone Low Salt/High Salt</title>
            <description>a low salt and a high salt diet were given consequently and randomly during a week at the end of the pioglitazone phase</description>
          </group>
          <group group_id="O2">
            <title>Placebo Low Salt/High Salt</title>
            <description>a low salt and a high salt diet were given consequently and randomly during a week at the end of the placebo phase</description>
          </group>
        </group_list>
        <measure>
          <title>Effects of Pioglitazone on Renal Hemodynamics</title>
          <description>At the end of each treatment diet phase, renal clearances were performed for the determination of GFR and RBF</description>
          <units>ml/min/1.73m2</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.0" spread="4.4"/>
                    <measurement group_id="O2" value="62.4" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Effects of Pioglitazone on Sodium and Lithium Clearances</title>
        <description>At the end of each treatment and diet phase, 24 urine collections were collected for the determination of sodium and lithium clearances</description>
        <time_frame>2007</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pioglitazone Low Salt/High Salt</title>
            <description>a low salt and a high salt diet were given consequently and randomly during a week at the end of the pioglitazone phase</description>
          </group>
          <group group_id="O2">
            <title>Placebo Low Salt/High Salt</title>
            <description>a low salt and a high salt diet were given consequently and randomly during a week at the end of the placebo phase</description>
          </group>
        </group_list>
        <measure>
          <title>Effects of Pioglitazone on Sodium and Lithium Clearances</title>
          <description>At the end of each treatment and diet phase, 24 urine collections were collected for the determination of sodium and lithium clearances</description>
          <units>ml/min</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.05" spread="0.10"/>
                    <measurement group_id="O2" value="1.18" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Effects of Pioglitazone on 24h Blood Pressure Control</title>
        <description>24 hour blood pressure measurements were performed after each treatment/diet phase</description>
        <time_frame>march 2009</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pioglitazone Low Salt/High Salt</title>
            <description>a low salt and a high salt diet were given consequently and randomly during a week at the end of the pioglitazone phase</description>
          </group>
          <group group_id="O2">
            <title>Placebo Low Salt/High Salt</title>
            <description>a low salt and a high salt diet were given consequently and randomly during a week at the end of the placebo phase</description>
          </group>
        </group_list>
        <measure>
          <title>Effects of Pioglitazone on 24h Blood Pressure Control</title>
          <description>24 hour blood pressure measurements were performed after each treatment/diet phase</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128" spread="5"/>
                    <measurement group_id="O2" value="129" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effects of Pioglitazone on Salt Sensitivity</title>
        <time_frame>2009</time_frame>
        <posting_date>06/2010</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Pioglitazone Low Salt/High Salt</title>
          <description>a low salt and a high salt diet were given consequently and randomly during a week at the end of the pioglitazone phase</description>
        </group>
        <group group_id="E2">
          <title>Placebo Low Salt/High Salt</title>
          <description>a low salt and a high salt diet were given consequently and randomly during a week at the end of the placebo phase</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The sample size may seem small but the cross over design of the study increased the statistical power. Each of 16 individuals was examined 4 times after the 4 different phases (pioglitazone-low salt, and high salt, placebo low salt and high salt).</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Zanchi Anne, MD</name_or_title>
      <organization>University Hospital Geneva and Lausanne, Switzerland</organization>
      <phone>0041213140775</phone>
      <email>azanchidel@hotmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

